RecruitingInterventional · Phase 1NCT02074839 ↗A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
RecruitingInterventional · Not applicableNCT02235857 ↗Treatment of Drug-resistant Pediatric Primary Focal Segmental Glomerulosclerosis Using the Liposorber® LA-15 SystemDarshana M DadhaniaPIInterventionDevice: LIPOSORBER® LA-15 SystemDatesMay 2015 – Sep 2027 (est.)SponsorKaneka Pharma America CorporationFocal Segmental Glomerulosclerosis
Active, not recruitingInterventional · Phase 2/3NCT02598661 ↗A Study to Evaluate Imetelstat (GRN163L) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) TreatmentPinkal DesaiPIInterventionDrug: Imetelstat Sodium · Drug: PlaceboDatesJan 2016 – Oct 2023· Results postedSponsorGeron CorporationMyelodysplastic Syndromes
Active, not recruitingInterventional · Phase 1/2NCT02773030 ↗Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 As Monotherapy and in Combination With Other Treatments in Subjects With Multiple MyelomaRuben NiesvizkyPIInterventionDrug: CC-220 · Drug: Dexamethasone · Drug: Daratumumab · Drug: Bortezomib · Drug: Carfilzomib · Drug: Daratumumab - 16mg/kg · Drug: Bortezomib (BTZ) · Drug: Daratumumab- 1800mgDatesOct 2016 – May 2024· Results postedSponsorCelgene CorporationMultiple Myeloma
RecruitingInterventional · Phase 2NCT02974647 ↗Phase II Multicenter Study of Ruxolitinib in Relapsed or Refractory T or NK Cell LymphomaJia RuanPIInterventionDrug: RuxolitinibDatesNov 2016 – Nov 2027 (est.)SponsorMemorial Sloan Kettering Cancer CenterLymphoma
Active, not recruitingInterventional · Phase 1/2NCT04086264 ↗A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid LeukemiaGail J RobozPIInterventionDrug: Azacitidine · Drug: IMGN632 · Drug: VenetoclaxDatesNov 2019 – Feb 2027 (est.)SponsorAbbVie Inc.Acute Myeloid Leukemia
RecruitingInterventional · Phase 1/2NCT04150497 ↗Open Label Dose-escalation and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART22 (Allogeneic Engineered T-cells Expressing Anti-CD22 Chimeric Antigen Receptor) in Patients With Relapsed or refractoryCD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL)Gail J RobozPIInterventionBiological: UCART22 · Biological: CLLS52DatesOct 2019 – Jun 2026 (est.)SponsorCellectis, IncB-cell Acute Lymphoblastic Leukemia
Active, not recruitingInterventional · Phase 1NCT04279847 ↗A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid NeoplasmsEllen K. RitchiePIInterventionDrug: INCB057643 · Drug: RuxolitinibDatesFeb 2021 – Apr 2027 (est.)SponsorIncyte CorporationMyelofibrosisMyelodysplastic SyndromeMyelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome+4 more
Active, not recruitingInterventional · Phase 1NCT04420754 ↗A Multicenter Phase I Study of AIC100 CAR T Cells in Relapsed and/or Refractory Advanced Thyroid Cancer or Anaplastic Thyroid CancerSebastian A. MayerPIInterventionBiological: AIC100 CAR T CellsDatesSep 2020 – Aug 2026 (est.)SponsorAffyImmune Therapeutics Inc.Anaplastic Thyroid CancerRelapsed/Refractory Poorly Differentiated Thyroid Cancer
RecruitingInterventional · Phase 1NCT05798897 ↗A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen-Specific T Cells (MT-601) Administered to Patients With Relapsed or Refractory Non-Hodgkin and Hodgkin Lymphoma (APOLLO)Caitlin K GribbinPIInterventionDrug: MT-601DatesJan 2023 – Feb 2028 (est.)SponsorMarker Therapeutics, Inc.Non-Hodgkin Lymphoma, AdultNon-Hodgkin Lymphoma, RefractoryNon-Hodgkin Lymphoma, Relapsed+4 more
RecruitingInterventional · Phase 3NCT06615479 ↗A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple MyelomaMateo Mejia SaldarriagaPIInterventionDrug: BMS-986393 · Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Daratumumab · Drug: Pomalidomide · Drug: Dexamethasone · Drug: CarfilzomibDatesMar 2025 – Dec 2027 (est.)SponsorJuno Therapeutics, Inc.Relapsed or Refractory Multiple Myeloma (RRMM)
RecruitingInterventional · Phase 1/2NCT06634589 ↗A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell MalignanciesJohn AllanPIInterventionDrug: Tacabrutideg · Drug: Sonrotoclax · Drug: Zanubrutinib · Drug: Mosunetuzumab · Drug: Glofitamab · Drug: ObinutuzumabDatesNov 2024 – Dec 2028 (est.)SponsorBeiGene USAB-cell MalignancyRelapsed CancerRefractory Cancer+1 more
RecruitingInterventional · Phase 1NCT07082803 ↗An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-121 as a Single Agent and in Combination With Other Anti-Lymphoma Agents, in Patients With Relapsed or Refractory Non-Hodgkin LymphomasErin MulveyPIInterventionDrug: TLN-121 · Drug: zeprumetostat (TLN-254)DatesJun 2025 – Sep 2030 (est.)SponsorTreeline Biosciences INCLymphomaLymphoma, Non Hodgkin
TerminatedInterventional · Phase 1NCT03218683 ↗A Phase 1/1b/2a, 3-Part, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 Monotherapy and in Combination With Venetoclax in Subjects With Relapsed or Refractory Haematologic MalignanciesPinkal DesaiPIInterventionDrug: AZD5991 · Drug: AZD5991 + VenetoclaxDatesAug 2017 – Oct 2021SponsorAstraZeneca Pharmaceuticals LPRelapsed or Refractory Acute Myeloid Leukemia (AML)
CompletedInterventional · Phase 2NCT03557359 ↗A Phase II, Open Label, Single Arm Study of Nivolumab for Recurrent or Progressive IDH Mutant Gliomas With Prior Exposure to Alkylating AgentsHoward Alan FinePIInterventionDrug: NivolumabDatesJun 2018 – Sep 2022· Results postedSponsorColumbia UniversityGliomas
TerminatedInterventional · Phase 1/2NCT03572634 ↗A Combined Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of TP-0903 in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)John AllanPIInterventionDrug: TP-0903 · Combination product: TP-0903 and ibrutinib combination therapyDatesJun 2019 – Jan 2020· Results postedSponsorTolero Pharmaceuticals Inc.Chronic Lymphocytic LeukemiaCLLSLL+1 more
CompletedInterventional · Phase 1NCT03625505 ↗A Multicenter, Open-Label Phase 1b Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Subjects With Relapsed/Refractory Acute Myeloid LeukemiaEllen K. RitchiePIInterventionDrug: Venetoclax · Drug: GilteritinibDatesOct 2018 – Aug 2021SponsorAbbVie Inc.Acute Myeloid Leukemia (AML)
CompletedInterventional · Phase 3NCT03651128 ↗A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)Roger N PearsePIInterventionBiological: bb2121 · Drug: Daratumumab · Drug: Pomalidomide · Drug: Dexamethasone · Drug: Bortezomib · Drug: Ixazomib · Drug: Lenalidomide · Drug: Carfilzomib · Drug: ElotuzumabDatesApr 2019 – Apr 2026SponsorCelgene CorporationMultiple Myeloma
TerminatedInterventional · Phase 2NCT03679624 ↗A Phase II Study of Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's MacroglobulinemiaJohn AllanPIInterventionDrug: Ibrutinib · Drug: DaratumumabDatesJul 2020 – Sep 2020· Results postedSponsorWeill Medical College of Cornell UniversityWaldenstrom MacroglobulinemiaWaldenstrom's DiseaseWaldenström+5 more
TerminatedInterventional · Phase 1/2NCT04113616 ↗An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)Gail J RobozPIInterventionDrug: KRT-232 · Drug: Cytarabine · Drug: DecitabineDatesSep 2019 – Sep 2023SponsorKartos Therapeutics, Inc.Relapsed or Refractory Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)